Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma

Retinoids are an important component of neuroblastoma therapy at the stage of minimal residual disease, yet 40–50% of patients treated with 13‐cis‐retinoic acid (13‐cis‐RA) still relapse, indicating the need for more effective retinoid therapy. Vorinostat, or Suberoylanilide hydroxamic acid (SAHA),...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Cheung, Belamy B., Tan, Owen, Koach, Jessica, Liu, Bing, Shum, Michael S.Y., Carter, Daniel R., Sutton, Selina, Po'uha, Sela T., Chesler, Louis, Haber, Michelle, Norris, Murray D., Kavallaris, Maria, Liu, Tao, O'Neill, Geraldine M., Marshall, Glenn M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528804/
https://ncbi.nlm.nih.gov/pubmed/25963741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.04.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados